QLT regains US Visudyne rights in "simplified" agreement with Novartis
This article was originally published in Scrip
Executive Summary
QLT has restructured an agreement with Novartis Pharma to regain exclusive commercial rights to its ophthalmic treatment Visudyne in the US from the beginning of next year.